Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
28 hedge funds and large institutions have $410K invested in Navidea Biopharmaceuticals Inc. in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
12% more funds holding
Funds holding: 25 → 28 (+3)
7% more capital invested
Capital invested by funds: $383K → $410K (+$27.3K)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
25% less call options, than puts
Call options by funds: $3K | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$40.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$23.5K |
| 3 |
ACM
Allred Capital Management
Dallas,
Texas
|
+$15.8K |
| 4 |
Renaissance Technologies
New York
|
+$9.88K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$5.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$48K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$11.4K |
| 3 |
Millennium Management
New York
|
-$10K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$3K |
| 5 |
VF
Virtu Financial
New York
|
-$1.14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KFS
26
Kelly Financial Services
Braintree,
Massachusetts
| $11 | – | – | – |
|
|
BCMLT
27
Beacon Capital Management LLC (Tennessee)
Franklin,
Tennessee
| $2 | – | – | – |
|
|
28
Group One Trading
Chicago,
Illinois
| – | -$48K | -190,752 | Closed |
|
|
29
Millennium Management
New York
| – | -$10K | -40,146 | Closed |
|
|
30
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$3K | -11,110 | Closed |
|
31
JP Morgan Chase
New York
| – | +$63 | +250 | +24% |
|
NAVB Hedge Fund Activity: Q4 2022 in Review
28 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2022, worth a combined $410K — up 7.1% from $383K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NAVB positions and 3 closed out — a net gain of 3 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Warberg Asset Management, opening a new position worth an estimated $40.3K. The largest seller was Group One Trading, exiting entirely with an estimated $48K sold.
- 28 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2022, up from 25 in Q3 2022.
- Funds reported $410K of Navidea Biopharmaceuticals Inc. stock for Q4 2022, up 7.1% quarter-over-quarter.
- 6 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2022 and 3 closed out, a net change of +3 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2022 was Warberg Asset Management, an estimated $40.3K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q4 2022 was Group One Trading, an estimated $48K sold.
Based on aggregated 13F filings for Q4 2022.